

Disclosure of total number of voting rights and number of shares in the capital at June 30, 2014

Paris, July 3, 2014 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
June 30, 2014	20, 682, 992	Theoretical number of voting rights: 20, 682, 992 (including treasury shares) Number of real voting rights: 20, 654, 050 (without treasury shares)

About BioAlliance Pharma

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products

Livatag[®] (Doxorubicin Transdrug[™]) (primary liver cancer): Phase III on going

Validive[®] (Clonidine Lauriad[®]) (mucositis): Phase II on going

Biotherapy AMEP[®]/Synfoldin (invasive melanoma): Preclinical and clinical Phase

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

BioAlliance Pharma SA

Judith Gréciet, CEO

Tel.: +33 1 45 58 76 01

Judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com